{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:32:54Z","timestamp":1793968374851,"version":"4.8.0"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Linezolid is an antibiotic used to treat infections caused by drug-resistant gram-positive organisms, including vancomycin-resistant\n                    <jats:italic toggle=\"yes\">Enterococcus faecium<\/jats:italic>\n                    , multi-drug resistant\n                    <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                    , and methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    . The adverse effects of linezolid can include thrombocytopenia and neuropathy, which are more prevalent with higher exposures and longer treatment durations. Although linezolid is traditionally administered at a standard 600 mg dose every 12 hours, the resulting exposure can vary greatly between patients and can lead to treatment failure or toxicity. The efficacy and toxicity of linezolid are determined by the exposure achieved in the patient; numerous clinical and population pharmacokinetics (popPK) studies have identified threshold measurements for both parameters. Several special populations with an increased need for linezolid dose adjustments have also been identified. Therapeutic Drug Monitoring (TDM) is a clinical strategy that assesses the response of an individual patient and helps adjust the dosing regimen to maximize efficacy while minimizing toxicity. Adaptive feedback control and model-informed precision dosing are additional strategies that use Bayesian algorithms and PK models to predict patient-specific drug exposure. TDM is a very useful tool for patient populations with sparse clinical data or known alterations in pharmacokinetics, including children, patients with renal insufficiency or those receiving renal replacement therapy, and patients taking co-medications known to interact with linezolid. As part of the clinical workflow, clinicians can use TDM with the thresholds summarized from the current literature to improve linezolid dosing for patients and maximize the probability of treatment success.\n                  <\/jats:p>","DOI":"10.1097\/ftd.0000000000000710","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T12:09:47Z","timestamp":1572005387000},"page":"83-92","source":"Crossref","is-referenced-by-count":116,"title":["Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics"],"prefix":"10.1097","volume":"42","author":[{"given":"Gauri G.","family":"Rao","sequence":"first","affiliation":[{"name":"UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Konicki","sequence":"additional","affiliation":[{"name":"UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, Department of Laboratory Medicine, Luigi Sacco University Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University of Sydney, Faculty of Medicine and Health, School of Pharmacy;"},{"name":"Westmead Hospital, Sydney, NSW, Australia;"},{"name":"Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J. E.","family":"Marriott","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases, St. Vincent's Hospital, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[{"name":"Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children's Hospital Los Angeles; and"},{"name":"Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the IATDMCT Antimicrobial Scientific Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0732-8893(91)90002-W","article-title":"Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against mycobacterium tuberculosis","volume":"14","author":"Ashtekar","year":"1991","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","article-title":"In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones","volume":"40","author":"Jones","year":"1996","journal-title":"Antimicrob Agents Chemother."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis","volume":"40","author":"Kaatz","year":"1996","journal-title":"Antimicrob Agents Chemother."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1469-0691.2000.006006331.x","article-title":"In vitro activity of linezolid against staphylococci","volume":"6","author":"Cuny","year":"2000","journal-title":"Clin Microbiol Infect."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.45.4.1295-1297.2001","article-title":"In vitro activities of linezolid against multiple nocardia species","volume":"45","author":"Brown-Elliott","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.45.7.2154-2156.2001","article-title":"Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci","volume":"45","author":"Prystowsky","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm Drug Dispos."},{"key":"R12-20230814","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/PCC.09r00853","article-title":"Linezolid and serotonin syndrome","volume":"11","author":"Quinn","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/17425255.2015.1098617","article-title":"Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones","volume":"11","author":"Douros","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1183\/09031936.00001913","article-title":"Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients","volume":"42","author":"Bolhuis","year":"2013","journal-title":"Eur Respir J."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and monte carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2169\/internalmedicine.54.3146","article-title":"Potential drug interaction between warfarin and linezolid","volume":"54","author":"Sakai","year":"2015","journal-title":"Intern Med."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/0885066610392893","article-title":"Clinical outcomes of linezolid vs vancomycin in methicillin-resistant staphylococcus aureus ventilator-associated pneumonia: retrospective analysis","volume":"26","author":"Chan","year":"2011","journal-title":"J Intensive Care Med."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.01378-08","article-title":"Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jinf.2014.08.010","article-title":"Experience with linezolid for the treatment of nocardiosis in organ transplant recipients","volume":"70","author":"De La Cruz","year":"2015","journal-title":"J Infect."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1345\/aph.1K196","article-title":"Linezolid for the treatment of nocardia spp. infections","volume":"41","author":"Jodlowski","year":"2007","journal-title":"Ann Pharmacother."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijantimicag.2018.04.022","article-title":"Bacteriological relevance of linezolid versus vancomycin in postoperative empirical treatment of osteoarticular infections: a retrospective single-center study","volume":"52","author":"Takoudju","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/14787210.3.3.343","article-title":"Role of linezolid in the treatment of orthopedic infections","volume":"3","author":"Bassetti","year":"2005","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"suppl 3","key":"R31-20230814","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving ronventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40268-015-0117-5","article-title":"Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: superiority of ctrough- over cmax-derived linear regression models","volume":"16","author":"Srinivas","year":"2016","journal-title":"Drugs R D."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/14656566.2016.1182154","article-title":"Risk factors associated with high linezolid trough plasma concentrations","volume":"17","author":"Morata","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"issue":"suppl 3","key":"R39-20230814","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1469-0691.2006.01577.x","article-title":"EUCAST technical note on linezolid","volume":"12","year":"2006","journal-title":"Clin Microbiol Infect."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.01194-06","article-title":"Pharmacokinetic\/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model","volume":"51","author":"Boak","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","article-title":"Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones","volume":"12","author":"Cattaneo","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bcp.12806","article-title":"A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?","volume":"81","author":"Pea","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00003495-200161040-00008","article-title":"Linezolid: a review of its use in the management of serious gram-positive infections","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2013.10.003","article-title":"Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations","volume":"94","author":"Garcia-Prats","year":"2014","journal-title":"Tuberculosis (Edinb)."},{"issue":"9 suppl","key":"R52-20230814","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/01.inf.0000086954.43010.63","article-title":"Linezolid pharmacokinetics in pediatric patients: an overview","volume":"22","author":"Jungbluth","year":"2003","journal-title":"Pediatr Infect Dis J."},{"key":"R53-20230814","first-page":"1","article-title":"Linezolid in children with drug resistant tuberculosis","volume":"0","author":"Shah","year":"2018","journal-title":"Infect Dis."},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/INF.0000000000002067","article-title":"Population pharmacokinetics of intravenous linezolid in premature infants","volume":"38","author":"Thibault","year":"2019","journal-title":"Pediatr Infect Dis J."},{"issue":"suppl 4","key":"R55-20230814","first-page":"iv23","article-title":"Clinical experience with linezolid in infants and children","volume":"66","author":"Garazzino","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy."},{"key":"R57-20230814","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents."},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10156-010-0080-6","article-title":"Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction","volume":"17","author":"Tsuji","year":"2011","journal-title":"J Infect Chemother."},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","article-title":"Pharmacokinetics of linezolid in subjects with renal dysfunction","volume":"47","author":"Brier","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"R61-20230814","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkv349","article-title":"Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother."},{"issue":"suppl 2","key":"R63-20230814","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"R64-20230814","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2017.06.023","article-title":"Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study","volume":"50","author":"Wicha","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"R65-20230814","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","article-title":"Pharmacokinetics of linezolid in critically ill patients","volume":"12","author":"Sazdanovic","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R66-20230814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.48.1.281-284.2004","article-title":"Linezolid pharmacokinetics in adult patients with cystic fibrosis","volume":"48","author":"Bosso","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"R67-20230814","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.05.009","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients","volume":"48","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R68-20230814","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-14-288","article-title":"How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect Dis."},{"key":"R69-20230814","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10826076.2011.555677","article-title":"High-throughput determination of linezolid in human plasma by liquid chromatography-tandem mass spectrometry","volume":"34","author":"Vlase","year":"2011","journal-title":"J Liq Chromatogr Relat Technol."},{"key":"R70-20230814","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpba.2012.04.007","article-title":"Rapid and sensitive LC\u2013MS\/MS method for the analysis of antibiotic linezolid on dried blood spot","volume":"67-68","author":"la Marca","year":"2012","journal-title":"J Pharm Biomed Anal."},{"key":"R71-20230814","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0b013e3181d3f5cb","article-title":"A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma","volume":"32","author":"Polillo","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R72-20230814","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/FTD.0b013e3181d5eeee","article-title":"Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection","volume":"32","author":"Cattaneo","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R73-20230814","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/bmc.597","article-title":"High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma","volume":"20","author":"Boak","year":"2006","journal-title":"Biomed Chromatogr."},{"key":"R74-20230814","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"R76-20230814","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"R77-20230814","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/imj.13412","article-title":"Individualised medicine: why we need Bayesian dosing","volume":"47","author":"Donagher","year":"2017","journal-title":"Intern Med J."},{"key":"R78-20230814","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/psp4.12353","article-title":"Model-informed precision dosing at the bedside: scientific challenges and opportunities","volume":"7","author":"Keizer","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R79-20230814","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40262-017-0606-5","article-title":"Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients","volume":"57","author":"Cojutti","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R80-20230814","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R81-20230814","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dki014","article-title":"Pharmacokinetic studies of linezolid and teicoplanin in the critically ill","volume":"55","author":"Whitehouse","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"R83-20230814","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R84-20230814","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R85-20230814","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1124\/dmd.106.013755","article-title":"Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R86-20230814","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R88-20230814","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R89-20230814","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R90-20230814","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R91-20230814","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scand J Infect Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T15:07:53Z","timestamp":1721920073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000710","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}